Status:
COMPLETED
Clinical Efficacy and SAfety of Intravenous Infusion of Nicorandil During Primary Percutaneous Coronary Intervention
Lead Sponsor:
Fudan University
Conditions:
ST Elevation Myocardial Infarction
Percutaneous Coronary Intervention
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The investigators evaluate the efficacy and safety of intravenous administration of nicorandil as adjuncts to reperfusion treatment in acute ST-segment elevation acute myocardial infarction (STEMI) pa...
Eligibility Criteria
Inclusion
- 18-80 years;
- acute ST-segment elevation myocardial infarction within 12 hours of symptom onset;
Exclusion
- systolic blood pressure\<100mmHg;
- cardiac shock;
- aortic dissection;
- history of myocardial infarction or percutaneous coronary intervention or coronary artery bypass grafting (\<6 month);
- history of the treatment of nicorandil (\<6 month);
- history of intravenous nitrates before percutaneous coronary intervention;
- contraindicated or intolerable to nicorandil;
- pregnant or lactation period;
- patients with an estimated survival time of less than 1 year.
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT04665648
Start Date
June 1 2021
End Date
December 31 2024
Last Update
March 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan Hospital
Shanghai, Shanghai Municipality, China, 200032